Easton Pharmaceuticals (OP: EAPH) Re- Enters Drug Market, Acquires 50% Ownership Interest in FSAD Drug And Related Patents / Patent Pendings. Drug Subsequently Underwent Clinical Trials at Cedars-Sinai Medical Center, Beverley Hills, CA.
9/16/2013 9:57:03 AM
TORONTO--(BUSINESS WIRE)--Easton Pharmaceuticals (OTC: EAPH - News), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announces It has re-entered the drug market by acquiring a 50 percent ownership interest in a Drug designed to treat (FSAD) Female Sexual Arousal Disorder (FSAD). The acquisition terms are for the issuance of 10,000,000 restricted shares of the company’s common stock, previously issued in escrow and an option to purchase additional shares should the drug be developed and brought to a certain stage utilizing FDA protocols.
Help employers find you! Check out all the jobs and post your resume.
comments powered by